Skip to main content

Drug Assays

More Thoughts on Compound Metrics

Over at Practical Fragments, Dan Erlanson has comments on the Michael Shultz paper that I wrote about here. He goes into details on some of the problems that turn up when you try to apply various compound metrics across a broad range of molecular weights and/or lipophilicities. In the most obvious example, the indices that are based on Heavy Atom Count (HAC) will jump around much more in the low-molecular-weight range, and none of the proposed refinements can quite fix this. And with the alternative LELP measure, you have to watch out when you’re at very low LogP values.
Shultz’s preferred LipE/LLE metric avoids that problem, and it’s size-independent as well. That part can be either a bug or a feature, depending on your perspective. For the most part, I think that’s useful, but in the early stages of fragment optimization, I think that a size-independent measurement is not what you want. The whole point in that stage is to pick the starting points with the most binding for their size, and a well-designed fragment library shouldn’t have too many big problems with lipophilicity (those will come along later). So I take Shultz’s point about the validity of LLE in general, but I think that I’ll be using it and either LE or BEI (HAC-driven and molecular-weight driven) measure of binding efficiency when I’m working in the fragment end of things. How to weight those will be a judgment call, naturally, but judgment calls are, in theory, what we’re being paid for, right?

3 comments on “More Thoughts on Compound Metrics”

  1. Teddy Z says:

    There is another discussion on metrics in general in the discussion here:

  2. ScientistSailor says:

    Maybe we should stack-rank people based on how many metrics they’ve invented…

  3. tert says:

    ScientistSailor, you think you’re joking, but you’re not. I’ve seen it with my own eyes…

Comments are closed.